Featured Education

Demystifying the Evolving Science and Potential Role of Incretins in T2D

Click here to learn more

Atypical Manifestations of Chronic GVHD

Click here to learn more

Help Your Patients Navigate Risk-benefit Assessment, Choose the Best Therapy for Them, and Mitigate TEAEs

Click here to learn more

Moving Towards Fixed-Duration Therapy in CLL and SLL

Click here to learn more

What You MUST Know About the Emerging Standard of Care for 1L Treatment of CLL and SLL

Click here to learn more

Treating Acquired Resistance and Evaluating Next-generation Therapies

Click here to learn more

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
Transitioning from Chemoimmunotherapy to More Targeted Approaches in MCL
  • Credit: 1.0hr(s)
  • CME, CPE, MOC, NCPD
  • October 14, 2022 — 
  • October 30, 2023
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology, Pathology
  • Specialties: Lymphoma, Mantle Cell Lymphoma
  • Location: Internet Activity Enduring
The natural history of mantle cell lymphoma (MCL) is a repeated pattern of remission and relapse; after a few relapses, patients have a very small chance of responding to any therapy. Considerable progress has been made over the last decade as the treatment paradigm has shifted from traditional chemoimmunotherapy toward targeted and cell-based therapies in both the frontline and relapsed/refractory (R/R) settings. However, selecting the best treatment is often complicated, involving multiple patient factors, and there is no established standard of care. During Transitioning from Chemoimmunotherapy to More Targeted Approaches in MCL, experts discuss using prognostic tools to plan treatment for individuals with MCL and targetable mutations, integrating emerging data and guidelines recommendations for front-line treatment, potential benefits and risks of chemotherapy-free targeted options, planning safe and effective use of novel therapies and combinations in the second- and third-line settings and for R/R MCL, and eradicating health inequities and closing the survival gap. This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.
Enroll Today
View Course
  • On-Demand
Potential Benefits of Incretins Beyond Glycemic Control in T2D
  • Credit: 1.0hr(s)
  • CME
  • October 14, 2022 — 
  • October 29, 2023
  • Therapeutic Areas: Diabetes, Endocrinology
  • Specialties: Diabetes, Endocrinology
  • Location: Internet Activity Enduring
Despite the growing list of safe and effective therapies for individuals with T2D, many patients struggle to achieve their glucose target and thus remain at risk for significant comorbidities. Novel unimolecular dual agonists may help address these unmet needs.  What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices? During the session, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes. This taped satellite symposium was derived from the 58th EASD Annual Meeting on September 19, 2022.
Enroll Today
View Course
  • On-Demand
Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part II: Treating Acquired Resistance and Evaluating Next-generation Therapies
  • Credit: 0.15hr(s)
  • AAPA, CME, CPE, NCPD
  • November 29, 2022 — 
  • November 28, 2023
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: Biomarkers, NSCLC
  • Location: Internet Activity Enduring
The evolution of the non-small cell lung cancer (NSCLC) treatment landscape and the discovery of predictive biomarkers that can be targeted by novel therapies or combinations is facilitating more individualized treatment. However, drug resistance plays a major role in therapeutic failure and clinicians must stay alert to the current and emerging treatment options to provide optimal care. Are you ready to test your skills amongst your colleagues? Join us for Part 2 of this question and answer based educational activity Treating Acquired Resistance and Evaluating Next-generation Therapies where our oncology experts will: Discuss treatment selection for patients with acquired resistance to targeted therapy Present the latest clinical evidence on new and emerging targeted therapies Provide strategies to promote patient engagement in their care
Enroll Today
View Course
  • On-Demand
Build Your Own Case Study: A Glimpse at Optimal T2D Management: Enhancing Outcomes with GLP-1 RAs
  • Credit: 1.0hr(s)
  • CME, CPE, NCPD, Physician Assistants
  • October 28, 2023 — 
  • October 27, 2023
  • Therapeutic Areas: Diabetes, Endocrinology
  • Specialties: Diabetes, Endocrinology
  • Location: Internet Activity Enduring
Think you fully understand the differences between available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their use in the management of Type 2 diabetes (T2D) and comorbidities? Clinicians may under-use GLP-1 RAs or not fully understand the differences between all the available GLP-1 RAs. As a result, unmet needs in T2D management persist, particularly in some ethnic and socioeconomic populations. Test your knowledge about newest guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2D using GLP-1 RAs by building your own case studies. This will help your patients achieve A1C targets, particularly those with comorbidities including obesity, cardiovascular disease, NAFLD/NASH, transplants, PCOS and more!  Additionally, this will help you identify various social determinants of health (SDoH) that may be unrecognizable and help you direct your patients in changing important modifiable behaviors (like sleep, stress, smoking cessation, and alcohol use). At any point in this Build Your Own Case Study, expert endocrinologists will shed light on current recommendations and evidence for GLP-1 RAs in the management of T2D along with obesity, cardiovascular diseases, and other comorbidities. Our expert faculty will also offer insights on individualizing treatment plans to help your patients reach their goals and reduce comorbidity risks. Think you have all the tools you need to help your patients? If so, post-test and claiming credit will be a breeze! 
Enroll Today
View Course
  • On-Demand
Making the Right Call: Biomarker Testing and Targeting in NSCLC: Part I: Equitable, Guideline-based Testing for Prognosis and Treatment
  • Credit: 0.30hr(s)
  • AAPA, CME, CPE, NCPD
  • November 29, 2022 — 
  • November 28, 2023
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: Biomarkers, NSCLC
  • Location: Internet Activity Enduring
In the past decade, advances in non-small cell lung cancer (NSCLC) have rapidly evolved with the discovery of targetable mutations and subsequent therapies. However, suboptimal biomarker testing practices and varying adherence to testing guidelines presents a challenge to implementing targeted treatment. Are you ready to test your skills against those of your colleagues? Join us for Part 1 of this question and answer based educational activity Equitable, Guideline-based Testing for Prognosis and Treatment where our oncology experts will: Review guideline recommendations for biomarker testing and treatment selection Present clinical evidence for the use of current and emerging targeted therapies Discuss health disparities in biomarker testing
Enroll Today
View Course
  • Clinical Pearl
GVHD-E3 | ECHO Program: Sclerotic Chronic GVHD
  • Credit: 1.0hr(s)
  • CME, NCPD
  • September 26, 2022 — 
  • September 26, 2023
  • Therapeutic Areas: Family Medicine / Primary Care, General Medicine
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care.     The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions. The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients.
Enroll Today
View Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List